Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...